MedinCell S.A. is a clinical-stage biopharmaceutical company specializing in the development of long-acting injectable therapies to improve treatment adherence and accessibility worldwide. Leveraging its proprietary BEPO® technology, a biodegradable polymer-based platform for sustained drug release, the company creates innovative formulations across various therapeutic areas, including schizophrenia, postoperative pain, contraception, and malaria. Notable products include UZEDY (mdc-IRM), a commercial long-acting risperidone injection for adult schizophrenia treatment in partnership with Teva Pharmaceuticals, which reported net sales growth from $117 million in 2024 to $191 million in 2025. Key pipeline candidates in Phase III trials are mdc-TJK, an olanzapine subcutaneous injection for schizophrenia with anticipated EU submission in Q2 2026, and mdc-CWM, a celecoxib formulation for reducing postoperative pain after knee replacement surgery in collaboration with Arthritis Innovation Corporation. Preclinical programs further expand its portfolio. Founded in 2003 and headquartered in Jacou, France, MedinCell S.A. employs around 140 international experts and partners with leading pharmaceutical firms and NGOs to address global health challenges while minimizing environmental impact through efficient drug delivery.